Executive Leadership

Mission

We are a full service, global pharmaceutical CRO lab that provides high quality service to our clients and provides opportunities for our employees in grow a career in a healthy work environment.

Vision

To become one of the best CROs in the world by providing the best service possible, using the best technical know-how at a reasonable value, to enable our clients to develop life-saving medications.

Values

Quality We are committed to excellence in the results we achieve, and how we achieve them.

Integrity Being honest, reliable and accountable in our words and behavior, doing the right things for our clients, company, community, and ourselves.

Respect for people. Promote a diverse culture and commitment to mutually respect our teammates, our customers, and people around us.

Collaboration Working together to achieve common goals is the foundation of our success; seek input and listen, and be flexible and responsive.

Song Li, Ph.D.

Song Li, Ph.D.

Founder and Honorary Chairman, Frontage Holdings Corp. and CEO, Frontage Laboratories, Inc.
Song Li, Ph.D.

Song Li, Ph.D.

Founder and Honorary Chairman, Frontage Holdings Corp. and CEO, Frontage Laboratories, Inc.

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products.

Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award,  the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC.

Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

Read Full Bio
Zeke Li, M.D.

Zeke Li, M.D.

CEO, Frontage Holdings Corp. and SVP, Frontage Laboratories, Inc.
Zeke Li, M.D.

Zeke Li, M.D.

CEO, Frontage Holdings Corp. and SVP, Frontage Laboratories, Inc.

Dr. Zeke Li is responsible for global project management functions and the company’s corporate strategy. As one of the founders and board members of Frontage, Dr. Li has more than 20 years of related experience that began with post-doctoral training at the National Institutes of Health. Prior to Frontage, he served as Group Leader, Preclinical and Pharmacology for Scios Inc., a Johnson and Johnson company. In recent years, Dr. Li has interacted extensively with Chinese biopharmaceutical companies on novel and generic development projects. With in-depth experience in research and development of small molecules, peptides and protein drugs, he has authored and co-authored more than 40 scientific papers and patents.

Dr. Li received his medical degree and a master’s degree in pathology from Norman Bethune University of Medical Sciences in China. He earned a doctor of philosophy degree in pathology from McGill University.

Read Full Bio
Joe (Yifeng) Gao

Joe (Yifeng) Gao

Chief Financial Officer (CFO)
Joe (Yifeng) Gao

Joe (Yifeng) Gao

Chief Financial Officer (CFO)

Joe has 18 years of experience in finance and accounting supporting large corporations and small start-ups. His expertise includes corporate and operational financing, investor relations, acquisition management, capital markets, accounting, FP&A, and process improvement.

Most recently, Joe spent 8 years as CFO for Baixing.Com, China’s second-ranked multi-category classifieds horizontal in terms of traffic. In this role, he was a key member of executive management team. Under Joe’s financial leadership, the company diversified its revenue base beyond classifieds, with new avenues in SaaS, bringing in $58 million U.S. in revenue in FY2017.

Prior to Baixing.Com, Joe was the Senior Audit Manager of Deloitte in Shanghai (2001-2006 and 2009-2011) and in New York (from 2006-2008). In this role, he was responsible for performing operational and financial audits for multi-national corporations and IPOs for various stock markets. He also was responsible to perform SOX 404 audits for US-listed companies and developing recommendations and reports based on results and presenting these ideas to senior management.

Joe received his B.A in Accounting from Shanghai International Studies University. He is a certified public accountant in the State of Maine and certified public accountant in China.

Read Full Bio
Hugh M. Davis, Ph.D.

Hugh M. Davis, Ph.D.

Chief Business Officer
Hugh M. Davis, Ph.D.

Hugh M. Davis, Ph.D.

Chief Business Officer

As the Chief Business Officer (CBO), Dr. Hugh Davis oversees Business Development, Sales, Marketing and Strategic Partnerships. Hugh has over 30 years of experience in the pharmaceutical industry. His most recent position was with Johnson & Johnson where he has served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001.  JBIO is responsible for creating and characterizing all biologic assets for J&J, across all therapeutic areas. In this role, Hugh participated in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Darzalex® and Tremfya®.  Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at Glaxo SmithKline from 1996 to 2001.

Hugh has published over 75 manuscripts in refereed journals, book chapters and invited review articles in areas of therapeutic drug discovery, clinical pharmacology and development in immunology, oncology, metabolic disease, bone metabolism and cardiovascular medicine.

Following receipt of his Bachelor’s degree in Chemistry from Gannon University in 1980 and Master’s and Doctorate degrees in Biochemistry from Villanova University in 1983 and 1985, Hugh completed a Post-Doctoral Fellowship at Centocor, Inc. where he patented the characterization of the CA 125 cancer antigen, a marker used in the diagnosis of ovarian cancer. Hugh has taught Chemistry, Biochemistry and Physics at Delaware County Community College, Immaculata University, Thomas Jefferson University and for 30 years at Villanova University, primarily teaching Allied Health majors in General, Biochemistry and Organic Chemistry.  Hugh is a member of the Villanova University College of Liberal Arts and Sciences Dean’s Advisory Council.

 

Read Full Bio
Tianyi Zhang Ph.D.

Tianyi Zhang Ph.D.

Executive Vice President of Frontage Laboratories, Inc and General Manager of Frontage China
Tianyi Zhang Ph.D.

Tianyi Zhang Ph.D.

Executive Vice President of Frontage Laboratories, Inc and General Manager of Frontage China

Dr Tianyi Zhang is a senior vice president of the Group and the general manager of Frontage Shanghai since January 2016. He is responsible for the general operation, financial performance and business growth of our China business. From December 2011 to December 2015, he was the vice president of Frontage Shanghai, responsible for bioanalytical/DMPK development and services in China. From June 2010 to November 2011, he worked at MPI Research Inc. as a director of operation and bioanalytical services. From April 2006 to June 2010, he was the lab manager of PPD Development, a subsidiary of Pharmaceutical Product Development Inc. From May 2004 to May 2006, he was the project manager of Tandem Labs, Inc., a subsidiary of NWT Inc. He was the senior research scientist of Bioanalytical Systems, Inc. before joining Tandem Labs, Inc.

Dr Zhang received his bachelor of science degree in chemistry and master of science degree in chemistry from Nanjing University, China, in July 1991 and July 1994, respectively. He then received his PhD degree in analytical chemistry from the University of Florida, United States, in July 2001 and his MBA degree from the Virginia Commonwealth University, United States, in June 2009. In addition, he has contributed over 60 scientific publications and reports.

Read Full Bio
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services
Dongmei Wang, Ph.D.

Dongmei Wang, Ph.D.

Executive Vice President, Global CMC Services

With more than 20 years of pharmaceutical and biotech industrial experience, Dr. Wang is responsible for the Global CMC (Chemistry Manufacture & Control) Services at Frontage, including analytical services, formulation development, and manufacturing of GLP preclinical tox batches & GMP clinical trial materials. Products includes oral formulations, topical and sterile injections & ophthalmic formulations for IND, NDA and ANDA filings. Prior to joining Frontage in February 2007, Dr. Wang served as the director of Analytical Chemistry at NovaDel Pharma Inc., where she led teams providing support for NDA product development, clinical supply manufacturing, CMC sections of 505(b)(2) filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed Pharmaceutical Analysis and Control department at Therics Inc. to support 3D printing product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.

Dr. Wang earned a PhD degree in Chemistry from Iowa State University, followed by postdoctoral research at the University of Chicago. She received a MS in Chemical Engineering from China Institute of Atomic Energy and a BS in Chemistry from Peking University in China.

Read Full Bio
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Bioanalytical and Biologics Services
John Lin, Ph.D.

John Lin, Ph.D.

Executive Vice President, Bioanalytical and Biologics Services

As Executive Vice President, Bioanalytical and Biologics Services, Dr. John Lin leads operations for the company’s global bioanalytical labs. Before joining Frontage, he served as a business leader in AstraZeneca’s global drug metabolism and pharmacokinetics (DMPK) division. Prior to AstraZeneca, Dr. Lin was Laboratory Director for Avantix Laboratories.

With more than 20 years of experience, Dr. Lin’s current research focus is in the area of bioanalytical method development and validation, dry blood spot (DBS) sampling with LC-MS/MS analysis, and biomarker quantification using LC-MS/MS. He has contributed to more than 20 research publications covering the development and validation of LC-MS/MS methods for the determination of small and large molecules in biological matrices, four book chapters and one technical patent. He is the invited reviewer for several international journals including the Journal of Pharmaceutical Biomedical Analysis (JPBA) and Journal of Chromatography B (JCB).

Dr. Lin earned a doctor of philosophy degree in analytical chemistry from Dalhousie University in Canada. He received a master’s degree in analytical chemistry from Yunnan University and a bachelor of science degree in chemistry from Fuzhou Branch School of Jiangxi Normal College. Dr. Lin completed post-doctoral research in pharmacokinetics and metabolism at the College of Pharmacy and the Comprehensive Cancer Center of the Ohio State University.

Read Full Bio
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President, DMPK Services
Abdul Mutlib, Ph.D.

Abdul Mutlib, Ph.D.

Executive Vice President, DMPK Services

Dr. Abdul Mutlib is Vice President of Drug Metabolism and Pharmacokinetics, and leads operations for this service group.  Prior to joining Frontage in 2010, he held director-level roles within drug metabolism teams at Wyeth and Pfizer. Earlier in his career, he held scientific positions on the drug metabolism teams at Hoechst-Roussel and DuPont-Merck.  With more than 20 years of experience in drug metabolism and analytical chemistry, Dr. Mutlib’s research includes application of various analytical techniques and stable isotope labeled compounds in elucidating structures of metabolites and metabolic pathways; mass spectrometry; qualitative and quantitative NMR; metabolism-mediated toxicities; reactive metabolites; phase II metabolism; drug-drug interactions; and toxicogenomics. He has published more than sixty papers in peer-reviewed journals.

Dr. Mutlib earned a bachelor’s degree in pharmacy and a doctor of philosophy degree in pharmaceutical chemistry from the University of Sydney in Australia. He completed post-doctoral fellowships at Universities of Washington and British Columbia.

Read Full Bio
Sridhar Krishnan

Sridhar Krishnan

Senior Vice President, Global Operations
Sridhar Krishnan

Sridhar Krishnan

Senior Vice President, Global Operations

Sridhar has over 25 years of experiences in operations and over 20 years of experience in pharmaceutical manufacturing and medical devices industries. He has proven track record of leading large, cross-functional global teams, driving enterprise wide business transformations, strategies, delivering improvements in operational performance, financial/business results and enhancing enterprise value. Sridhar comes to us from Catalent Pharma Solutions, where he spent 9.5 years as part of the leadership team. Most recently he was the Vice President, Global Procurement and Business Analytics where he oversaw all direct, indirect and capital expenditures managing spend little over $1Bln across enterprise wide. He also served as Vice President, Global Operations where he led the company’s transformation, increase EBITDA by 58% and drove the successful IPO launch. Sridhar also worked for GE Healthcare for 14 years and held several leadership positions in Global Supply Chain Operations & Quality. Sridhar received a BE in Mechanical Engineering from Bangalore University, India. He is a certified Master Black Belt in Lean Six Sigma from GE.

Read Full Bio